Sciele Pharma Announces That Addrenex Has Completed Enrollment Of Pivotal Phase III Trial For Clonicel For ADHD

Sciele Pharma, Inc. (NASDAQ: SCRX), a specialty pharmaceutical company, announced that Addrenex Pharmaceuticals has completed patient enrollment of its first Phase III clinical trial in the U.S. for Clonicel to treat attention deficit and hyperactivity disorder (ADHD) in children. ...

Write comment to this article:

Subject:

Name:

email or site:

Code: